Home » Health & Medicine, World » Global Regenerative Therapies Market is Expected to Reach US$ 18 Bn by 2022 – Persistence Market Research
“Global Regenerative Therapies Market”
The global regenerative therapies market has been estimated to be valued at US$ 5,286.2 Mn by the end of 2015, and is projected to witness stable growth across all global regions, which is attributed to the rising demand for fulfilling unmet clinical needs for longer sustainability and faster outcome treatments within a shorter time span.

According to the latest market report published by Persistence Market Research, titled ‘Global Market Study on Regenerative Therapies: Asia Pacific & Japan to Witness Highest Growth by 2022’, the global regenerative therapies market is expected to expand at a CAGR of 20.0% during the forecast period 2016 – 2022.  

Rising per capita healthcare expenditure and contribution to GDP, increasing funding & government support for the development of regenerative therapies, as well as surge in incidences of chronic diseases are major factors driving the growth of the global regenerative therapies market currently.  

By tissue type, the allografts segment is expected to remain the largest segment, registering the highest CAGR of 22.8% in terms of value, over the forecast period. The long-term effectiveness of the treatment and higher its higher biocompatibility with the patient is expected to contribute to the rise in its popularity over the forecast period. The allografts tissue type segment is expected to reach a market value of US$ 11,633.2 Mn by the end of the forecast period. The allografts tissue is also expected to emerge as the most preferred tissue type for both patients and physicians, globally, over the forecast period. The second most popular tissue type choice is xenografts, which are basically prepared by using various animal tissues.

Full Report Overview and Analysis@ http://www.persistencemarketresearch.com/market-research/regenerative-therapies-market.asp

The absence of standard regulations and legislations is leading to the invasion of many local players in both the developed and emerging regions. Moreover, high gestation period and time-to-market due to lengthy clinical trials, a large number of product recall within a short span post-approval, and lack of financial backing by smaller firms are among the major factors hampering the growth of regenerative therapies market currently. 

North America market is estimated to dominate the overall regenerative therapies market, accounting for a maximum value share of the global market by the end of 2016. By 2022, North America and Europe markets are expected to account for over three-fourth revenue share of the global regenerative therapies market. In terms of value, North America is estimated to be the dominant market, expanding at a CAGR of 19.7% over the forecast period.

Download Report TOC (table of content) at http://www.persistencemarketresearch.com/market-research/regenerative-therapies-market/toc

 

Some key companies covered in this report include Acelity L.P. Inc., Mesoblast Ltd., Nuo Therapeutics, Inc. (Cytomedix), Astellas Pharma US, Inc., Organovo Holdings Inc., Orgenesis Inc., Sanofi, Athersys, Inc., Shire Pharmaceuticals Limited, and Cytori Therapeutics Inc.

 

Request for Sample Report: http://www.persistencemarketresearch.com/samples/10598

Media Contact
Company Name: Persistence Market Research
Contact Person: Rahul Singh
Email: rahul@persistencemarketresearch.com
Phone: 6465687751
Address:305 Broadway, 7th Floor
City: New York
State: NY
Country: United States
Website: http://www.persistencemarketresearch.com/

Comments are closed.